RBC Capital Maintains Outperform on Viridian Therapeutics, Raises Price Target to $38
Benzinga Newsdesk 1 month ago
Analyst RatingsNewsPrice Target
RBC Capital analyst Lisa Walter maintains Viridian Therapeutics (NASDAQ:VRDN) with a Outperform and raises the price target from $36 to $38.
RBC Capital analyst Lisa Walter maintains Viridian Therapeutics (NASDAQ:VRDN) with a Outperform and raises the price target from $36 to $38.